Cargando…
Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Spine Surgery
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401842/ https://www.ncbi.nlm.nih.gov/pubmed/28443172 http://dx.doi.org/10.4184/asj.2017.11.2.272 |
_version_ | 1783231117223002112 |
---|---|
author | Ohtori, Seiji Orita, Sumihisa Yamauchi, Kazuyo Eguchi, Yawara Aoki, Yasuchika Nakamura, Junichi Suzuki, Miyako Kubota, Gou Inage, Kazuhide Shiga, Yasuhiro Abe, Koki Fujimoto, Kazuki Kanamoto, Hirohito Inoue, Masahiro Kinoshita, Hideyuki Furuya, Takeo Koda, Masao |
author_facet | Ohtori, Seiji Orita, Sumihisa Yamauchi, Kazuyo Eguchi, Yawara Aoki, Yasuchika Nakamura, Junichi Suzuki, Miyako Kubota, Gou Inage, Kazuhide Shiga, Yasuhiro Abe, Koki Fujimoto, Kazuki Kanamoto, Hirohito Inoue, Masahiro Kinoshita, Hideyuki Furuya, Takeo Koda, Masao |
author_sort | Ohtori, Seiji |
collection | PubMed |
description | STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years. METHODS: We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery. RESULTS: We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (p>0.05). CONCLUSIONS: This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis. |
format | Online Article Text |
id | pubmed-5401842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean Society of Spine Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-54018422017-04-25 Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? Ohtori, Seiji Orita, Sumihisa Yamauchi, Kazuyo Eguchi, Yawara Aoki, Yasuchika Nakamura, Junichi Suzuki, Miyako Kubota, Gou Inage, Kazuhide Shiga, Yasuhiro Abe, Koki Fujimoto, Kazuki Kanamoto, Hirohito Inoue, Masahiro Kinoshita, Hideyuki Furuya, Takeo Koda, Masao Asian Spine J Clinical Study STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years. METHODS: We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery. RESULTS: We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (p>0.05). CONCLUSIONS: This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis. Korean Society of Spine Surgery 2017-04 2017-04-12 /pmc/articles/PMC5401842/ /pubmed/28443172 http://dx.doi.org/10.4184/asj.2017.11.2.272 Text en Copyright © 2017 by Korean Society of Spine Surgery http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Ohtori, Seiji Orita, Sumihisa Yamauchi, Kazuyo Eguchi, Yawara Aoki, Yasuchika Nakamura, Junichi Suzuki, Miyako Kubota, Gou Inage, Kazuhide Shiga, Yasuhiro Abe, Koki Fujimoto, Kazuki Kanamoto, Hirohito Inoue, Masahiro Kinoshita, Hideyuki Furuya, Takeo Koda, Masao Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title | Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title_full | Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title_fullStr | Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title_full_unstemmed | Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title_short | Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis? |
title_sort | does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401842/ https://www.ncbi.nlm.nih.gov/pubmed/28443172 http://dx.doi.org/10.4184/asj.2017.11.2.272 |
work_keys_str_mv | AT ohtoriseiji doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT oritasumihisa doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT yamauchikazuyo doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT eguchiyawara doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT aokiyasuchika doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT nakamurajunichi doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT suzukimiyako doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT kubotagou doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT inagekazuhide doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT shigayasuhiro doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT abekoki doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT fujimotokazuki doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT kanamotohirohito doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT inouemasahiro doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT kinoshitahideyuki doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT furuyatakeo doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis AT kodamasao doesdiscontinuingteriparatidetreatmentandreplacingitwithbisphosphonatemaintainthevolumeofthebonefusionmassafterlumbarposterolateralfusioninwomenwithpostmenopausalosteoporosis |